Last 12 months
Inside the activity.
0 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2021 Filed Apr 26, 2021 21:48 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0001077183-21-000113 · wf-form4_161947371579723.xml · derivative · entry 4 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires 2023-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 19, 2018, Dr. Weiss was granted 20,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:48 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionCommon Stock | 9,378 | $28.33 | $265,678.74 |
DisclosureSEC source: 0001077183-21-000113 · wf-form4_161947371579723.xml · nonDerivative · entry 3 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:48 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionCommon Stock | 9,005 | $19.60 | $176,498.00 |
DisclosureSEC source: 0001077183-21-000113 · wf-form4_161947371579723.xml · nonDerivative · entry 2 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:48 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionCommon Stock | 6,667 | $9.22 | $61,469.74 |
DisclosureSEC source: 0001077183-21-000113 · wf-form4_161947371579723.xml · nonDerivative · entry 1 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:19 UTC |
Mallon MarkDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 151,016 | $0.00 Strike: $49.34 | $0.00 |
DisclosureSEC source: 0001077183-21-000111 · wf-form4_161904358115470.xml · derivative · entry 2 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,016 Underlying: Common Stock · 151,016 shares Expires 2028-04-19 F1 · derivative.exercise_date: On April 19, 2021, Mr. Mallon was granted 151,016 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:19 UTC |
Mallon MarkDirector · Chief Executive Officer
|
GrantCommon Stock | 55,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000111 · wf-form4_161904358115470.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,736 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC |
McKenzie Kathryn BChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 35,171 | $53.17 Strike: $53.17 | $1,870,042.07 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · derivative · entry 8 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,171 Underlying: Common Stock · 35,171 shares Expires 2028-03-02 F7 · derivative.exercise_date: On March 2, 2021, Ms. McKenzie was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC |
McKenzie Kathryn BChief Financial Officer
|
GrantCommon Stock | 6,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · nonDerivative · entry 3 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,535 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC |
McKenzie Kathryn BChief Financial Officer
|
Tax withholdingCommon Stock | 432 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,328 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
GrantCommon Stock | 56,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000086 · wf-form4_161482073084569.xml · nonDerivative · entry 4 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474,716 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:19 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 2,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000086 · wf-form4_161482073084569.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,418,293 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:18 UTC |
Bonello WilliamPresident, Informatics
|
GrantStock Option (Right to Buy) · Derivative | 24,619 | $53.17 Strike: $53.17 | $1,308,992.23 |
DisclosureSEC source: 0001077183-21-000085 · wf-form4_161482070863668.xml · derivative · entry 8 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,619 Underlying: Common Stock · 24,619 shares Expires 2028-03-02 F7 · derivative.exercise_date: On March 2, 2021, Mr. Bonello was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:18 UTC |
Bonello WilliamPresident, Informatics
|
GrantCommon Stock | 4,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000085 · wf-form4_161482070863668.xml · nonDerivative · entry 3 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,473 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:18 UTC |
Bonello WilliamPresident, Informatics
|
Tax withholdingCommon Stock | 432 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000085 · wf-form4_161482070863668.xml · nonDerivative · entry 2 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,128 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
Pedulla Denise EGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 24,619 | $53.17 Strike: $53.17 | $1,308,992.23 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · derivative · entry 8 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,619 Underlying: Common Stock · 24,619 shares Expires 2028-03-02 F7 · derivative.exercise_date: On March 2, 2021, Ms. Pedulla was granted 24,619 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
Pedulla Denise EGeneral Counsel
|
GrantCommon Stock | 4,345 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · nonDerivative · entry 3 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,643 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
Pedulla Denise EGeneral Counsel
|
Tax withholdingCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · nonDerivative · entry 2 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,298 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:18 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantStock Option (Right to Buy) · Derivative | 10,551 | $53.17 Strike: $53.17 | $560,996.67 |
DisclosureSEC source: 0001077183-21-000084 · wf-form4_161482068265167.xml · derivative · entry 8 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,551 Underlying: Common Stock · 10,551 shares Expires 2028-03-02 F7 · derivative.exercise_date: On March 2, 2021, Ms. Balliet was granted 10,551 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:18 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantCommon Stock | 1,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000084 · wf-form4_161482068265167.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,457 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:18 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Tax withholdingCommon Stock | 173 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000084 · wf-form4_161482068265167.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,595 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantStock Option (Right to Buy) · Derivative | 38,688 | $53.17 Strike: $53.17 | $2,057,040.96 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · derivative · entry 7 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,688 Underlying: Common Stock · 38,688 shares Expires 2028-03-02 F6 · derivative.exercise_date: On March 2, 2021, Mr. Shovlin was granted 38,688 stock options. These options vest ratably over the first four anniversary dates of the grant date Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantCommon Stock | 6,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · nonDerivative · entry 3 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,747 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Tax withholdingCommon Stock | 608 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,920 F2 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
Dieter Cynthia JChief Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 7,034 | $53.17 Strike: $53.17 | $373,997.78 |
DisclosureSEC source: 0001077183-21-000081 · wf-form4_161482060774746.xml · derivative · entry 3 Dieter Cynthia J · CIK 0001815335 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,034 Underlying: Common Stock · 7,034 shares Expires 2028-03-02 F2 · derivative.exercise_date: On March 2, 2021, Ms. Dieter was granted 7,014 stock options. These options vest ratably over the first four anniversary dates of the grant date Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:17 UTC |
Dieter Cynthia JChief Accounting Officer
|
GrantCommon Stock | 1,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000081 · wf-form4_161482060774746.xml · nonDerivative · entry 1 Dieter Cynthia J · CIK 0001815335 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,846 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:16 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
GrantStock Option (Right to Buy) · Derivative | 35,171 | $53.17 Strike: $53.17 | $1,870,042.07 |
DisclosureSEC source: 0001077183-21-000080 · wf-form4_161482057286973.xml · derivative · entry 7 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,171 Underlying: Common Stock · 35,171 shares Expires 2028-03-02 F5 · derivative.exercise_date: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:16 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
GrantCommon Stock | 6,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000080 · wf-form4_161482057286973.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,109 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:16 UTC |
Weiss Lawrence MartinChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 29,895 | $53.17 Strike: $53.17 | $1,589,517.15 |
DisclosureSEC source: 0001077183-21-000079 · wf-form4_161482054396633.xml · derivative · entry 6 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,895 Underlying: Common Stock · 29,895 shares Expires 2028-03-02 F5 · derivative.exercise_date: On March 2, 2021, Dr. Weiss was granted 29,895 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:16 UTC |
Weiss Lawrence MartinChief Medical Officer
|
GrantCommon Stock | 5,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000079 · wf-form4_161482054396633.xml · nonDerivative · entry 1 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,797 Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 02:06 UTC |
Brown Douglas MatthewChief Strategy Officer
|
GrantStock Option (Right to Buy) · Derivative | 26,378 | $53.17 Strike: $53.17 | $1,402,518.26 |
DisclosureSEC source: 0001077183-21-000089 · wf-form4_161490996623773.xml · derivative · entry 3 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,378 Underlying: Common Stock · 26,378 shares Expires 2028-03-02 F2 · derivative.exercise_date: On March 2, 2021, Mr. Brown was granted 26,378 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2021 Filed Mar 5, 2021 02:06 UTC |
Brown Douglas MatthewChief Strategy Officer
|
GrantCommon Stock | 4,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000089 · wf-form4_161490996623773.xml · nonDerivative · entry 1 Brown Douglas Matthew · CIK 0001849414 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,644 Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:19 UTC |
McKenzie Kathryn BChief Financial Officer
|
Tax withholdingCommon Stock | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000087 · wf-form4_161482075291006.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,760 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:19 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 2,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000086 · wf-form4_161482073084569.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,420,451 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:18 UTC |
Bonello WilliamPresident, Informatics
|
Tax withholdingCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000085 · wf-form4_161482070863668.xml · nonDerivative · entry 1 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,560 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:17 UTC |
Pedulla Denise EGeneral Counsel
|
Tax withholdingCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000083 · wf-form4_161482066513083.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,514 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:18 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Tax withholdingCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000084 · wf-form4_161482068265167.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,768 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:17 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Tax withholdingCommon Stock | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000082 · wf-form4_161482063651429.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,528 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,269 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · derivative · entry 11 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,269 shares Expires 2026-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,017 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · derivative · entry 10 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,017 shares Expires 2023-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · derivative · entry 9 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 25, 2017, Mr. Jones was granted 10,000 stock options. The options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · derivative · entry 8 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On April 20, 2016, Mr. Jones was granted 100,000 stock options. The options vested ratably over the first three anniversary dates of the grant date. On December 30, 2019, Mr. Jones transferred these options to Aspen Select Opportunity Fund, LP. F2 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionCommon Stock | 4,269 | $22.52 | $96,137.88 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · nonDerivative · entry 7 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of a stock option. No shares of Common Stock were sold by the Mr. Jones, and the shares of Common Stock received upon exercise of the stock option are subject to a lock-up agreement with BofA Securities, Inc, .Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionCommon Stock | 3,017 | $11.60 | $34,997.20 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · nonDerivative · entry 6 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of a stock option. No shares of Common Stock were sold by the Mr. Jones, and the shares of Common Stock received upon exercise of the stock option are subject to a lock-up agreement with BofA Securities, Inc, .Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionCommon Stock | 10,000 | $7.27 | $72,700.00 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · nonDerivative · entry 5 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of a stock option. No shares of Common Stock were sold by the Mr. Jones, and the shares of Common Stock received upon exercise of the stock option are subject to a lock-up agreement with BofA Securities, Inc, .Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 22:24 UTC |
JONES STEVEN CDirector
|
Exercise / conversionCommon Stock | 100,000 | $7.15 | $715,000.00 |
DisclosureSEC source: 0001077183-21-000053 · wf-form4_161040387992653.xml · nonDerivative · entry 4 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 1,100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This filing relates to the exercise of a stock option. No shares of Common Stock were sold by the Mr. Jones, and the shares of Common Stock received upon exercise of the stock option are subject to a lock-up agreement with BofA Securities, Inc, .Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC. F2 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| December 14, 2020 Filed Dec 14, 2020 22:49 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 25,000 | $51.67 | $1,291,750.00 |
DisclosureSEC source: 0001077183-20-000225 · wf-form4_160798614957845.xml · nonDerivative · entry 7 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 1,000,000 F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 01:51 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,005 | $0.00 Strike: $19.60 | $0.00 |
DisclosureSEC source: 0001077183-20-000227 · wf-form4_160808347590230.xml · derivative · entry 11 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,017 Underlying: Common Stock · 9,005 shares Expires 2024-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On March 1, 2019, Dr. Weiss was granted 36,022 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 01:51 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001077183-20-000227 · wf-form4_160808347590230.xml · derivative · entry 10 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 Underlying: Common Stock · 16,666 shares Expires 2023-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On December 12, 2018, Dr. Weiss was granted 25,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 01:51 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,333 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0001077183-20-000227 · wf-form4_160808347590230.xml · derivative · entry 9 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 13,333 shares Expires 2023-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On April 19, 2018, Dr. Weiss was granted 20,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 01:51 UTC |
Weiss Lawrence MartinChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001077183-20-000227 · wf-form4_160808347590230.xml · derivative · entry 8 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On May 25, 2017, Dr. Weiss was granted 20,000 stock options. These options vested ratably over the first three anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.